Cardinal Health price target raised to $150 from $142 at Mizuho

Mizuho analyst Steven Valiquette raised the firm’s price target on Cardinal Health (CAH) to $150 from $142 and keeps an Outperform rating on the shares. The firm, which currently expect tariffs to be fairly neutral as Pharma may offset Medical, made no changes to its model for tariffs or for FDA layoffs, but increased EPS estimates for additional expected M&A accretion. The firm increased its FY25 EPS estimate to $8.00 from $7.95, its FY26 estimate to $9.05 from $8.85 and its FY27 forecast to $10.13 from $9.75, the analyst noted.